Ethnicity and Cancer Scholar
Over the past two years, the New York Genome Center (NYGC) has created a regional, multi-institution research program, called Polyethnic-1000 (P-1000), to study the role of ethnicity in the incidence, pathophysiology, prevention, diagnosis, and treatment of many types of cancer. P-1000 now seeks an outstanding clinician-investigator to fill a new role, the Ethnicity and Cancer Scholar.
NYGC is seeking an Ethnicity and Cancer Scholar to play a major role in the conduct and coordination of clinical research related to racial disparities in cancer. The Scholar will serve as co-PI on the Polyethnic-1000 project, be part of its Steering Committee, participate in strategic decision-making for the program, lead the operational management of the project, and act as a liaison between the Center and collaborating institutions. The role will be a co-appointment (50%) between the NYGC and a local academic health center, with salary support to be determined based on the credentials of the selected candidate. The Ethnicity and Cancer Scholar will report to the Senior Scientific Director, Cancer Genomics and will have the Clinical Research Coordinator as a direct report. The Ethnicity and Cancer Scholar will lead the coordination with participating P-1000 sites and work closely with an inter-institutional team of scientific and administrative staff to manage the study-related activities at the NYGC. The Ethnicity and Cancer Scholar will participate in day to day oversight of Polyethnic-1000 activities, working closely with all P-1000 sites, NYGC Project Management, the P-1000 Clinical Research Coordinator, the NYGC Clinical Lab, NYGC Computational Biology, and NYGC Leadership. The candidate will be engaged in all aspects of the Polyethnic-1000 Program, including grant and protocol development and oversight, and budget management.
In consultation with the P-1000 Principal Investigators, the Steering Committee, and other NYGC senior team members, the Scholar will:
- Contribute to strategic decision-making for the Polyethnic-1000 study, in conjunction with the Principal Investigator(s), Steering Committee, and NYGC Leadership. This includes the development of accurate, feasible and comprehensive timelines, budget, metrics and deliverables; maintenance of a master protocol, quality standards and metrics; and overseeing the development of a data analysis and sharing plan;
- Engage with and visit clinical sites to provide study information, discuss the study protocol, develop a site, patient and sample sourcing strategy, review site feasibility, perform enrollment forecasts, and work with area partners with patients to continuously optimization and troubleshoot project workflow;
- Oversee the clinical annotation of samples in RedCap;
- Provide support to the NYGC Clinical Laboratory on review and return of results to clinicians;
- Engage with clinical and research sites to set up a patient and community outreach working group;
- Together with the P-1000 Project Manager, Clinical Research Coordinator, and Steering Committee ensure that the study protocol remains updated and compliant;
- With support from the Steering Committee, identify and engage funding agencies and apply to grants to support P1000, including participating as an investigator on new grant applications;
- Provide leadership and oversight to the Clinical Research Coordinator and Project Management on activities such as:
- writing the Polyethnic-1000 multi-site master protocol, in conjunction with the PI(s), consulting other internal teams to ensure that it is robust and accurate;
- quality control of specimen procurement;
- training community hospital staff in the protocol, including consent and sample collection to ensure quality and data integrity;
- writing SOPs, workflows and study documentation in line with the IRB to facilitate patient sample collection and processing, and other project processes;
- providing metrics for project oversight;
- contributing to progress reports, as required by funders;
- Provide NYGC’s senior leadership regular reports on Polyethnic-1000 progress, input on project prioritization, plans of action for managing backlogs, and involve leadership in key project decision-making.
- Communicate across the consortium as needed and maintain strong relationships with academic investigators and clinicians at partner and community hospitals.
- Provide at least 50% effort to this project, for a period of at least 2 years, while continuing to maintain some activities at their home institution.
We expect the Ethnicity and Cancer Scholar to be least a junior faculty member (Instructor or Assistant Professor) at an academic health center affiliated with the NYGC and/or P-1000. Clinical training in Oncology or affiliated subspecialties, eligibility for board certification, and a NYS medical license are desirable.
- Technical and Professional Skills: Consistently demonstrates skills and knowledge relevant for current role; strives to expand the depth and breadth of technical and professional skills; works with a high level of integrity; exhibits focus and discipline; appropriately prioritizes, manages expectations and delivers on commitments.
- Collaborative & Communicative: Models collaboration and teamwork; brings out the best in others; effectively works with all levels, internally and externally; respects and embraces diversity of perspective; communicates clearly and listens carefully; uses good judgment as to what to communicate and when to do so.
- Adaptable & Innovative: Adaptable and embraces change; develops new insights and pursues improvements and efficiency; fosters exchange of new ideas and willing to challenge the status quo; takes initiative and is solution-oriented; engages in work with passion and curiosity.
- Leader and Manager: Attracts, develops and retains diverse talent to achieve outstanding results; encourages professional development, coaches and regularly communicates expectations and feedback; aligns and inspires efforts toward our mission; translates organizational vision into action; responsibly utilizes NYGC’s human and financial resources to ensure organizational and financial health; uses good judgment when making decisions; pushes boundaries and generates new ideas.
Background on Polyethnic-1000
The Polyethnic-1000 (P-1000) initiative, overseen by the Genome Center Cancer Group (GCCG) at the New York Genome Center (NYGC), has formed a coalition of over 15 New York regional hospitals and research centers to study cancer genomics in patients belonging to ethnic minority populations. Recent advances in DNA sequencing technologies have revolutionized approaches to the prevention, risk assessment, early detection, diagnosis, and treatment of cancers. However, many ethnic groups, especially non-European minorities, have been significantly under-represented in cancer research, including in clinical trials with breakthrough drugs, and have not received equal benefits in clinical practice. As a result, our current knowledge about tumor biology, cancer risk, and response to treatment has primarily been derived from patients of European descent. These inequities limit our understanding of many aspects of cancer, and exacerbate health disparities in the United States. With the Polyethnic-1000 Program, we address both the scientific and social issues of health care inequities, by creating a dynamic research platform within the greater New York area that promises to enhance the ways in which cancer is prevented, diagnosed, and treated. The Polyethnic-1000 is establishing a framework to enhance interactions among our region’s academic and health centers to advance cancer genomics for all.
After demonstrating the ability to collect and analyze archival tissue samples in a retrospective manner, the P-1000 coalition is now building capacity to conduct prospective studies, by integrating additional modalities including patient recruitment with broad consent; integration of clinical data; expanded specimen collection (tumor tissue with matched normal sample); and data generation for molecular profiling, followed by clinical confirmation and return of actionable mutations to treating physicians. With this goal, we have submitted a generic tissue collection protocol for IRB approval, which will allow prospective sample collection and sequencing, and we launched a request for research proposals from the local cancer research community. These proposals will be reviewed by an independent review panel, with projects beginning in the fall of 2020. In the meantime, we are further developing the program’s outreach to those communities impacted by an increased prevalence of, and worsened outcomes from, cancer.
About the New York Genome Center
The New York Genome Center (NYGC) is an independent, nonprofit, academic research organization dedicated to advancing genomic research. NYGC scientists and staff are developing new approaches to diagnosing and treating neurological diseases and cancer through their expertise in whole genome sequencing, RNA sequencing, state-of-the art analytics, and development of advanced genomic tools. NYGC focuses its disease research in the following areas: cancer, neuropsychiatric disease (autism, schizophrenia, bipolar disease); and neurodegenerative disease (ALS, Alzheimer’s, Parkinson’s, Huntington’s).
Located in Lower Manhattan, the New York Genome Center was founded by and remains closely affiliated with twelve leading academic medical centers and research universities in the New York region and beyond, engaging in research projects with and for these institutions. Essential to our collaborative work is an outstanding core faculty, whose members hold a joint appointment at one of our NYGC partner universities. The core faculty support our scientific mission by conducting independent research in areas of mutual interest to us and the wider scientific community.
The New York Genome Center (NYGC) launched a collaborative effort in 2018 with leaders of the New York City cancer research community who have joined together to advance cancer genomics and its practice in clinical care by leveraging the City’s famously large and diverse population. The vision of this project, called Polyethnic-1000, is to deepen our understanding of the contributions diverse ethnicities make to the incidence and behavior of cancers, thereby improving outcomes for patients with distinct ethnic backgrounds, especially those underserved communities who currently lack access to the most recent advances in medical science. This will be achieved by bringing genomic innovation to patient populations generally under-represented in research and hence deprived of the benefits of scientific progress.
The New York Genome Center is a VEVRAA Federal Contractor. All qualified applicants will receive consideration for employment and will not be discriminated against on the basis of race, creed, color, gender, religion, national origin, sexual orientation, age, disability, genetic predisposition or carrier status, protected veteran or military status, domestic violence victim status, partnership status, caregiver status, alienage or citizenship status, marital status, or any other characteristic protected by applicable law. The New York Genome Center takes affirmative action in support of its policy to hire and advance in employment individuals who are minorities, women, protected veterans, and individuals with disabilities.
FLSA Status – Exempt
This position is eligible for visa sponsorship.